June 14, 2023 – Cala announced today that it launched its next-generation Cala kIQ system, a wearable device that delivers therapy for neurological disorders. The San Mateo, California-based company develops the Cala Trio device for transcutaneous afferent patterned stimulation (TAPS) therapy. Cala designed the Trio device for treating tremor. Its kIQ system delivers therapy for action […]
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the outcomes from a recent end-of-Phase 2 meeting with the U. S. Food and Drug Administration (FDA) […]
March 23, 2023–(BUSINESS WIRE)–Cala, the bioelectronic medicine leader setting a new standard of care for chronic disease, today announced meeting the primary endpoint on an interim analysis of a prospective, randomized, controlled study. This study, “RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor” (clinicaltrials.gov NCT05540626), demonstrated that adding TAPS therapy to […]
Praxis Precision Medicines has reported topline data from the Phase IIb Essential1 trial of ulixacaltamide (PRAX-944) to treat essential tremor (ET). The placebo-controlled, randomised, dose range finding, double-blind trial has been designed for assessing the safety, tolerability, and efficacy of once-a-day 60mg or 100mg ulixacaltamide treatment against a placebo after 56 days.
Insightec announced today that it received additional FDA approval for treating essential tremor with its Exablate Neuro platform. Essential tremor commonly affects both sides of the body, Insightec noted in a news release. The new approval allows appropriate patients to receive treatment on their second side at least nine months after treatment of the first side.
SAN MATEO, Calif.–(BUSINESS WIRE)–Cala, the bioelectronic medicine leader setting a new standard of patient care for chronic disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has set a payment determination and benefit category for the existing unique Healthcare Common Procedure Coding System (HCPCS) code K1018 for Cala TAPS therapy, initially put […]
Cala Health recently published a post-market surveillance study that demonstrates the long-term efficacy of its wrist-based wearable for people with essential tremor, finding that the device reduced patients’ tremor power by 71%. The Burlingame, California-based company was founded in 2014 as a Stanford University spinout. It makes a wrist-based wearable that uses electrical stimulation to temporarily relieve tremor symptoms.
The International Essential Tremor Foundation will bring together experts, scientists, patients, and family members for a day of learning about essential tremor. Lenexa, Kansas – The first ever Essential Tremor Virtual Education Conference will take place Saturday, October, 29, 2022, from 9 AM to 1 PM (CST). Hosted by the International Essential Tremor Foundation (IETF), […]
SAN MATEO, Calif., May 18, 2022–(BUSINESS WIRE)–Cala Health, the bioelectronic medicine leader setting a new standard of patient care for chronic disease, today announced new clinical research presented at ISPOR 2022. The study, titled “Co-Morbidities and Mechanistic Similarities of Essential Tremor and Parkinson’s Disease and Resulting Diagnostic Challenges,” analyzed comorbidities among patients diagnosed with essential tremor and […]
BOSTON, May 09, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update, including a video highlighting recent business and pipeline progress, and reported financial results for the first quarter […]